Vanguard Group Inc. Has $212.32 Million Stock Holdings in 10x Genomics $TXG

Vanguard Group Inc. lessened its holdings in 10x Genomics (NASDAQ:TXG) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,017,914 shares of the company’s stock after selling 256,418 shares during the period. Vanguard Group Inc. owned about 0.10% of 10x Genomics worth $212,322,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Geneos Wealth Management Inc. acquired a new stake in shares of 10x Genomics in the fourth quarter worth $38,000. Caprock Group LLC boosted its position in shares of 10x Genomics by 59.4% in the fourth quarter. Caprock Group LLC now owns 190,913 shares of the company’s stock worth $3,114,000 after buying an additional 71,110 shares during the period. M&T Bank Corp boosted its position in shares of 10x Genomics by 258.5% in the fourth quarter. M&T Bank Corp now owns 73,188 shares of the company’s stock worth $1,194,000 after buying an additional 52,771 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of 10x Genomics by 7.3% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 108,215 shares of the company’s stock worth $1,763,000 after buying an additional 7,333 shares during the period. Finally, Optas LLC boosted its position in shares of 10x Genomics by 66.1% in the fourth quarter. Optas LLC now owns 22,383 shares of the company’s stock worth $365,000 after buying an additional 8,906 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,826 shares of 10x Genomics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the sale, the insider directly owned 424,779 shares in the company, valued at $7,892,393.82. The trade was a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Taich sold 8,968 shares of 10x Genomics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $166,625.44. Following the completion of the sale, the chief financial officer owned 288,417 shares of the company’s stock, valued at $5,358,787.86. This trade represents a 3.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 46,426 shares of company stock worth $902,695 over the last ninety days. 8.84% of the stock is currently owned by insiders.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported Q1 revenue of $150.8 million and EPS of -$0.10, both better than Wall Street expectations, with revenue up 9.4% year over year and gross margin improving. Article: 10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
• Positive Sentiment: William Blair reiterated a Buy rating, citing strong Q1 results, an improved growth outlook tied to Atera, and attractive valuation. Article: 10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
• Neutral Sentiment: The company’s earnings call transcript and earnings coverage are drawing attention as investors look for more detail on management’s plans and the sustainability of margin improvement. Article: 10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Despite the beat, 10x Genomics still posted a loss and remains unprofitable, and the company’s FY2026 revenue outlook of $600 million to $625 million is only modestly above consensus. Article: 10x Genomics Reports First Quarter 2026 Financial Results

Analyst Ratings Changes

TXG has been the subject of several research reports. Leerink Partners decreased their price target on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a report on Tuesday, January 27th. Zacks Research upgraded shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a report on Friday, April 17th. Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a report on Friday, March 27th. Stifel Nicolaus raised their price target on shares of 10x Genomics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Barclays raised their price target on shares of 10x Genomics from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, 10x Genomics has a consensus rating of “Hold” and an average price target of $20.82.

10x Genomics Trading Down 3.7%

TXG opened at $21.60 on Friday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -127.06 and a beta of 2.05. 10x Genomics has a 1 year low of $8.06 and a 1 year high of $26.44. The stock has a fifty day moving average price of $21.53 and a 200 day moving average price of $18.96.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.19. The firm had revenue of $150.84 million during the quarter, compared to analysts’ expectations of $146.41 million. 10x Genomics had a negative return on equity of 2.89% and a negative net margin of 3.55%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.28) earnings per share. As a group, sell-side analysts forecast that 10x Genomics will post -0.93 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.